June 13, 2026

US$800 billion in index funds must now buy Rocket Lab shares

Electron small launch vehicle of the Rocket Lab Mission to Venus

The buy order that nobody placed

Rocket Lab will join the Nasdaq-100 index effective Monday, June 22, becoming the first New Zealand-founded company to sit among the 100 largest non-financial stocks on Nasdaq. The inclusion is not honorary. More than 200 funds worldwide track the index, and products linked to it account for over US$800 billion globally. Every one of those funds must now hold Rocket Lab shares in proportion to its weighting. The buying is automatic, non-discretionary, and already being priced in.

Shares jumped more than 9% on the announcement, pushing the company to an all-time high valuation of NZ$30.48 billion. The stock then added a further 5.9% in afterhours trading. Sir Peter Beck’s estimated wealth rose by US$164 million in a single session to US$2.0 billion.

For business owners watching from New Zealand, the significance is structural. Index membership changes the type of capital sitting on a company’s register. It brings large, sticky institutional money that holds through volatility and trades infrequently. That deeper liquidity makes it easier to raise capital, negotiate acquisitions, and attract the kind of partners who use index membership as a proxy for legitimacy.

The numbers backing it up

The Nasdaq-100 does not admit companies on sentiment alone. Rocket Lab’s operational trajectory earned the seat. The company posted record Q1 2026 revenue of US$200.3 million, up 63.5% year-on-year, with Q2 guidance of US$225-$240 million. Its record backlog of US$2.2 billion is up 20.2% quarter-on-quarter, and GAAP gross margins hit 38.2% in the quarter.

Critically, this is no longer a pure launch business. Spacecraft and satellite components now account for 68% of total revenue, creating a more recurring revenue base less dependent on individual missions. The company has completed more than 80 successful launches deploying over 250 satellites, with its components enabling more than 1,700 missions across commercial, defence, and national security work.

The balance sheet has strengthened in parallel. Total assets reached US$2.82 billion as of March 31, while convertible debt was slashed from US$152.4 million to US$36.9 million. The company holds more than US$2 billion in total liquidity.

32,000 Kiwis are along for the ride

The retail investor angle is striking. 32,000 New Zealanders now hold Rocket Lab shares through Sharesies, up from 20,000 when the bull run began in mid-2025. Their average buy price of US$12.76 means most are sitting on roughly a threefold paper gain. Sharesies has even added Rocket Lab to its self-select KiwiSaver scheme, with several hundred customers allocating retirement savings to the stock.

The broader space sector rally helps explain the momentum. SpaceX’s anticipated IPO at a US$75 billion valuation has lifted listed peers, with Virgin Galactic surging 22% overnight on the same day.

The valuation question nobody wants to answer

Here is where the celebration needs a reality check. Rocket Lab’s price-to-sales ratio sits at approximately 110x. That is extraordinary even for a high-growth tech stock. Analyst sentiment is positive, with 10 buy ratings, one overweight, four holds, and no sells, but the consensus 12-month price target of US$99.24 is roughly 13.5% below the post-announcement trading price. The analysts, in other words, think the index-driven rally has outrun the fundamentals.

The mechanical buying from index rebalancing is finite. Once June 22 passes, that automatic demand disappears. What remains is whether a US$2.2 billion backlog, the Neutron medium-class rocket expected to compete directly with SpaceX when it launches later this year, and a growing defence contract pipeline can justify a valuation that assumes near-flawless execution for years.

Rocket Lab has earned this milestone. The revenue growth is real, the backlog is tangible, and the shift from launch provider to vertically integrated space systems company is genuine. But 110x revenue is not a valuation that tolerates stumbles. The global money now flowing in will be patient, but it is not forgiving.

Sources

Subscribe for weekly news

Subscribe For Weekly News

* indicates required